ASH 2018 | VTE in cancer patients treated with immunotherapy
Alok Khorana
• 3 Dec 2018
The development of venous thromboembolism (VTE) is associated with the majority of the standard blood cancer treatments. Although novel agents have reduced levels of toxicity and side effects, VTE still occurs. Alok Khorana, MD, discusses a study conducted at the Cleveland Clinic, Cleveland, OH, which looked at the number of VTE events in patients receiving immunotherapy with ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab or durvalumab. This data was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
